How peptides get approved (or don’t)

Before a new peptide can be sold as a medicine, it has to survive a long, expensive sequence of tests. The stages are broadly the same worldwide:

• Preclinical. Lab and animal studies to see whether the molecule does anything useful and whether it is grossly toxic. Most candidates die here. Crucially, animal data alone tells you almost nothing about whether something works in people — plenty of research chemicals sold online never get past this stage.
• Phase 1. First tests in humans, usually a small group of healthy volunteers. The question is is it safe and what dose is tolerated, not does it work.
• Phase 2. A few hundred patients who actually have the condition. Does it show signs of working, and what are the side effects?
• Phase 3. Large trials, often thousands of patients across many sites, comparing the drug against placebo or existing treatment. This is where most candidates fail and where the evidence for approval is built.
• Approval. The company submits everything to a regulator, which reviews the data and decides whether the benefits outweigh the risks for a defined use.
• Phase 4. After approval, ongoing monitoring in the real world catches rarer side effects that trials were too small to see.

This is why a peptide like semaglutide took many years and trials in tens of thousands of people before it could be prescribed, while a powder labelled “research use only” has skipped the entire process.

Approval is granted by a national or regional regulator, and each one runs its own review. The three that matter most for English-language readers are:

• FDA (US Food and Drug Administration) — approves medicines for the United States.
• EMA (European Medicines Agency) — coordinates approval across the European Union.
• MHRA (UK Medicines and Healthcare products Regulatory Agency) — approves medicines for Great Britain, a separate process since Brexit.

They look at largely the same trial data and reach the same conclusion most of the time, but not always. Each weighs risk and benefit under its own rules, on its own timetable, and a company may simply choose not to apply in a given market. The practical result is that a drug can be approved in one region and unavailable, or still under review, in another — even when the science is identical.

A regulator never approves a peptide in the abstract. It approves it for a specific indication — a named condition, dose and patient group, backed by trials in exactly that setting. The same molecule can be approved for one use and unapproved for everything else.

Tesamorelin, for example, is FDA-approved for a single narrow indication and nothing else. Semaglutide was first approved for type 2 diabetes, then separately for weight management, each requiring its own trials. Using an approved drug for a purpose it was never tested for is “off-label” use — legal for a doctor to do, but not the same as that use being proven. And a peptide such as sermorelin may have once held an approval that was later withdrawn, leaving it in a grey zone. So “is this peptide approved?” is always really the question “approved for what?”

The most confusing situation is when a peptide is a licensed medicine in some countries but an unapproved research chemical in others. This is regulatory asymmetry, and it is common.

Cerebrolysin, a peptide mixture marketed for stroke and dementia, is licensed and prescribed in parts of Europe, Asia and the former Soviet states, yet it has never been approved by the FDA or sits outside the standard EU approval framework. Thymosin alpha-1 is an approved immune-modulating drug in several countries but is not FDA-approved in the US. Newer peptides like retatrutide are still in trials and not yet approved anywhere.

Why does this happen? Different regulators set different evidence bars; trials that satisfy one agency may not satisfy another; a manufacturer may never apply in a market it sees as too small or too costly; and historical or political factors shape which drugs entered which systems decades ago. None of this means an asymmetrically-approved peptide is fake — but it does mean “approved in country X” can reflect a lower or simply different evidence standard than you might assume.

Marketing leans hard on the word “approved” because it sounds like a guarantee. It is not. An approval tells you that one regulator judged the benefits to outweigh the risks for one defined use, given the data available at that time. It does not tell you the drug is safe for other uses, in other people, or that the evidence would clear a stricter regulator.

This is exactly why we grade every peptide on the strength of its human evidence and note its regulatory status region by region, rather than treating a single foreign licence as a green light. When you see a peptide described as “clinically approved”, ask three questions: approved by whom, for what, and on the basis of how much human evidence? Read how we grade evidence and the legal picture for the full approach.